Chronic Kidney Disease
Conditions
Interventions
telmisartan 20 mg for 4 weeks and up-titrating telmisartan to 40 mg at 4 weeks and continuing the same dose until 104 weeks
telmisartan 20 mg for 4 weeks and up-titrating telmisartan to 40 mg at 4 wee
Sponsors
Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are included if they are at least 20 years of age, chronic kidney disease stage 3-4 with estimated glomerular filtration rate of 15-60 ml/min/1.73 m2, receiving anti hypertensive therapy, and have sustained blood pressure control
Exclusion criteria
Exclusion criteria: heavy liver dysfunction and/or poor bile secretion, possibility of pregnancy or lactation, past history of hypersensitivity for telmisartan or its analogous drugs, nephrotic proteinuria, corticosteroids or immunosuppressant agents within the past 6 months, acute myocardial infarction within 6 months, congestive heart failure, cerebral infarction, transient ischemic attack, and renal artery stenosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A composite of doubling serum creatinine, transition to chronic kidney disease stage 5, the onset of end-stage renal disease, or death from any causes within 104 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Amount of urinary protein, and decreased eGFR during the 104 weeks. | — |
Countries
Japan
Contacts
Public ContactTomoya Nishino
Nagasaki University Hospital Nephrology
Outcome results
None listed